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ABSTRACT
miR122 is the prevalent miRNA in adult healthy liver and it is responsible for 
liver stem cell differentiation towards hepatocyte lineage. Its expression is frequently 
lost in hepatocellular carcinoma (HCC). We studied the effects of restoring miR122 
expression in a distinctive cell line derived from human HCC-BCLC9 cells-with a 
solid stem-like cell profile, high tumor initiating ability and undetectable miR122 
expression. We generated a stable BCLC9 cell line that expresses miR122 (BCLC9-
miR122). Restitution of miR122 in BCLC9 cells, decreases cell proliferation rate and 
reduces significantly tumor size in vivo. BCLC9-miR122 cells down-regulate expression 
of MYC, KLF4, FOXM1, AKT2 and AKT3 genes and up-regulate FOXO1 and FOXO3A gene 
expression. In addition, miR122 transfected cells decreased AKT2 kinase activation 
while decreased FOXO1 and FOXO3A protein inactivation. Reduction in tumor size 
in BCLC9-miR122 associated with an increase in p38MAPK protein expression 
and activation leading to a low phospho-ERK1/2 to phospho-p38 ratio. Treatment 
of miR122 positive cells with an inhibitor of TGFBR1 activation, abolished tumor 
dormancy program and recovered cell proliferation rate through a Smad-independent 
TGF-β response. 
HCC stem-like cells can be directed towards cell differentiation and tumor 
dormancy by restoring miR122 expression. We demonstrate, for the first time, 
that dormancy program is achieved through a Smad-independent TGF-β pathway. 
Reestablishing miR122 expression is a promising therapeutic strategy that would 
work concurrently reducing tumor aggressiveness and decreasing disease recurrence. 
INTRODUCTION
MicroRNAs (miRs) are regulators of gene expression 
by destabilizing and inducing degradation of messenger 
RNAs (mRNA) and/or repressing their translation [1]. 
miRs are key in cancer biomarker research due to their 
tissue specificity [2]. For instance, miR122 accounts for 
72% of all miRs in the liver and it is undetectable in all 
other tissues analyzed [3]. Besides the well-known role 
of miR122 in favoring hepatitis C virus replication in 
hepatocytes [4], its function in the normal adult liver is 
related to cholesterol and lipid homeostasis [5]. miR122 
expression increases along with liver development. It 
reaches its maximum levels in adult healthy liver and is 
associated with hepatocyte differentiation. Up to 70% of 
hepatocellular carcinomas (HCC) show miR122 down-
regulation [6] and the same applies for HCC-derived cell 
lines [7]. Several studies forcing expression of miR122 
in HCC cell lines, describe miR122 as a liver tumor 
suppressor [8] and hepatocyte cell differentiation factor [9]. 
HCC remains one of the leading causes of cancer-
related death in the world [10]. Despite the improvement 
in patient prognosis due to earlier diagnosis and new 
treatment strategies, long term effective therapy for 
advanced disease and prevention of tumor recurrence 
are still an unmet need [11]. This is probably favoured 
by the presence of a subpopulation of transformed cells 
with high tumor initiating ability that are known as cancer 
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stem cells (CSCs) or tumor initiating cells (TICs). BCLC9 
is a unique cell line derived from human HCC [12] that 
exhibits a wide range of stem cell markers, self-renewal 
ability, they usually grow forming spheroid structures 
on standard plastic culture plates and they show high 
tumor-initiating potential. So, as far as we know, this is 
the unique human hepatocarcinoma cell line with a well-
founded cancer stem cell phenotype. Since no other human 
HCC cell line offers this profile, there is no possibility to 
verify our results in other liver cell line although effects of 
miR122 on differentiation of non-transformed progenitor 
cells are well reported. Accordingly, restoring miR122 
expression in HCC cells with CSC phenotype will depict 
the mechanisms involved in the tumor suppressor impact 
of miR122 and it will provide valuable information about 
potential therapeutic targets for refractory/recurrent HCC. 
RESULTS
miR122 increases adherence of cell spheroids 
and down-regulates pluripotency markers  
in vitro
BCLC9 cell line was established from a well-
differentiated human HCC [12] and they show a stem cell 
phenotype characterized by gene and protein expression 
of a pool of pluripotency markers: OCT4, NANOG, SOX2, 
KLF4, CD133, EpCAM, KRT19 genes, and overexpression 
of MYC which is not due to MYC gene amplification 
(Supplementary Figure S1A–S1C). BCLC9 cells have 
been authenticated by ATCC as human origin, and not a 
match for any other profile in the ATCC or DSMZ Short 
Tandem Repeat (STR) databases. We used Fluorescence In 
Situ Hybridization (FISH) to confirm BCLC9 karyotype 
previously described for this cell line [12] (Supplementary 
Figure S2). BCLC9 usual growth pattern is non-adherent 
spheroid-like structures with a high nucleus to cytoplasmic 
ratio and they are highly efficient tumor initiating cells 
in SCID mice. Since BCLC9 cells do not express 
miR122, they are the perfect setting to analyze the effects 
of restoring miR122 expression in CSC-like human 
HCC cells. So, we generated a stable BCLC9 cell line 
expressing miR122 by plasmid transfection and confirmed 
its expression by real-time PCR (Figure 1A). BCLC9-
miR122 cells show adherent phenotype (Figure 1B) 
different from that of parental cells. We analyzed the 
presence of pluripotency cell markers to pinpoint miR122 
role in cell differentiation. Only two of the genes tested-
MYC and KLF4-were significantly down-regulated in 
BCLC9-miR122 cells, while CD133 and EpCAM genes 
were up-regulated (Figure 1C). We also confirmed a 
significant decrease in MYC protein load in BCLC9-
miR122 cells (Figure 1D). Thus, miR122 might act as 
a differentiation factor in BCLC9 cells since it down-
regulates two out of the four master pluripotency genes: 
OCT4, SOX2, KLF4, and MYC [13]. 
miR122 reduces cell proliferation and tumor 
progression in vivo
We performed cDNA microarray analysis in three 
independent batches of both parental BCLC9 cells and 
BCLC9-miR122 cells grown in vitro. Samples were 
hybridized to Human Genome U219 array plate. A total 
of 2432 genes that were differentially expressed (1215 
genes were up-regulated and 1217 down-regulated) 
in BCLC9-miR122 compared to BCLC9 cells with a 
FDR < 0,05 (p < 0,05), were used for the analysis using 
Ingenuity® Pathways AnalysisTM (IPA) (http://www.
ingenuity.com, Ingenuity® Systems, Redwood City, CA, 
USA). Genes were mapped to genetic networks available 
in the IPA database and ranked by score. Results of IPA 
analysis showed a clear enrichment in cell cycle, DNA 
replication, recombination and repair, and cancer pathways 
(Supplementary Figure S3A, S3C).
We analyzed BCLC9 and BCLC9-miR122 cell 
cycle by flow cytometry in physiologic conditions, this 
allowed us to know the percentage of cells alive in each 
phase. Analysis revealed a high percentage of BCLC9 
and BCLC9-miR122 cells in Sub G0/G1 and G0/G1 
phases (Figure 2A). However, BCLC9-miR122 show a 
significantly higher Sub G0/G1 cell population compared 
to BCLC9. In vitro cell proliferation assays along time 
demonstrate that miR122 reduces significantly cell 
proliferation rate (Figure 2B). These results are supported 
by the significant down-regulation of cyclins: Cyclin A2 
(CCNA2), Cyclin E1 (CCNE1) and Cyclin G1 (CCNG1) 
and up-regulation of p21 (CDKN1A) and p15 (CDKN2B) 
shown by array platform, and confirmed by real-time PCR 
(Figure 2C). To check miR122 effects on cell proliferation 
in vivo, we injected 1·106 of parental BCLC9 or BCLC9-
miR122 cells in SCID mice. Thirty days after injection, 
mice were sacrificed and tumors were collected and 
measured, and maximum tumor diameter was registered. 
All mice from both groups developed tumors, although 
tumors originated from BCLC9-miR122 cells were 
significantly smaller than those generated by parental cells 
(Figure 2D). 
Mature miR122 was positively localized in 
hepatocytes of all tumors from BCLC9-miR122 cells 
(Supplementary Figure S3B). These results ruled out the 
possibility that BCLC9-miR122 tumors developed from 
BCLC9-miR122-negativized cells.
miR122 triggers dormancy program 
TGF-β is an anti-mitogenic cytokine that turns 
into oncogenicity in advanced tumors [14]. We analyzed 
the potential role of TGF-β pathway in BCLC9-miR122 
cells, because the mechanism of TGF-β growth arrest 
is related to the inhibition of MYC expression [15] and 
the induction of both p21 and p15 genes [16]. Moreover, 
SMAD4 pathway is listed as an activated pathway in 
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Figure 1: miR122 changes CSC profile and cell adherence capability. (A) Mature miR122 levels in parental and miR122-
transfected BCLC9 cells determined by real-time PCR and related to healthy liver. Results are normalized to RNU6B gene. (B) Cell 
adherence in parental and miR122 transfected cells. Scale bars, 50 μm. (C) OCT4, NANOG, SOX2, CD133, MYC, EpCAM, and KLF4 gene 
expression determined by real-time PCR, in BCLC9-miR122 relative to parental cells. Results normalized against RPLP0 gene. (D) IB 
analysis of MYC in purified nuclear fractions of parental and BCLC9-miR122 cells, β-Actin is loading control. 
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Figure 2: miR122 delays cell proliferation and cell cycle progression. (A) Flow Cytometry cell cycle analysis in unfixed 
BCLC9 parental cells (top) and BCLC9-miR122 cells (bottom) in physiologic conditions using Hoechst 33342 and PI as non-vital DNA 
dye. Graphic shows the percentage of cells in each cell cycle phase. (B) Cell growth kinetics at different time points (t = 0, 24, 48, 72 and 
144 hours) of cell culture. (C) CCNA2, CCND1, CCNE1, CCNG1, CDKN1A, CDKN2A, and CDKN2B gene expression determined by real-
time PCR, in BCLC9-miR122 relative to parental cells. Results normalized against RPLP0 gene. (D) Comparison of major tumor diameters 
(mm) and representative tumors generated by BCLC9 and BCLC9-miR122 cell injection in SCID mice.
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IPA analysis  (Supplementary Figure S3C) in BCLC9-
miR122 cells. We also confirmed the induction of two 
TGF-β target genes different from those directly involved 
in cell cycle progression: TGF-β Induced (TGFBI) and 
TGF-β Receptor 3 (TGFBR3) in BCLC9-miR122 cells 
(Supplementary Figure S3D). Since TGF-β pathway seems 
to be activated in miR122 transfected cells, we analyzed 
SMAD2 and SMAD3 status to confirm a potential shift 
of TGF-β towards a cytostatic role. Neither SMAD2 nor 
SMAD3 expression and activation, change depending 
on the presence of miR122 in vitro (Figure 3A, 3B) or in 
vivo (Figure 3C). To discard any contribution of TGF-β 
pathway in BCLC9-miR122 cells, we treated transfected 
and parental cells with an inhibitor of TGF-β type 1 
receptor phosphorylation: TGF-β-R1 kinase inhibitor II 
(II, 2-(3-(6-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-
naphthyridine). BCLC9-miR122 cells treated with 1 µM 
of TGF-β-R1 inhibitor for 48 hours significantly increases 
cell proliferation rate when compared to untreated cells 
(Figure 3D). 
Alternative TGF-β signaling pathways such are 
activation of ERKs, JNKs and p38 MAP kinases have 
been described [17]. Besides, recent reports link cancer 
cell dormancy with a shift in ERK1/2:p38 ratio [18], 
high p38 over ERK1/2 levels is characteristic of cell 
dormancy while lower p38 over ERK1/2 is critical for 
fast growing tumors. To determine if BCLC9-miR122 
tumors are going into a dormant state and the potential 
role of TGFβ pathway in this condition, expression 
of ERK1/2, and p38 and their phosphorylated forms 
in parental BCLC9 and BCLC9-miR122 cells were 
analyzed in vitro. We observed a significant increase in 
the percentage of activated p38 in miR122 transfected 
cells compared to parental cells (Figure 4A, 4B), inducing 
a low phosho-ERK1/2:phospho-p38 ratio (Figure 4C). 
TGF-β-R1 inhibition decreases the percentage of 
phospho-p38 while further increases phospho-ERK1/2 
levels These results confirm that treatment with TGF-
β-R1 inhibitor reverts BCLC9-miR122 dormancy towards 
a proliferative condition due to a significant reduction in 
p38 activation (Supplementary Figure S4A). Regarding 
ERK1/2, p38 expression and their activated forms in 
xenograft tumors, we observed that BCLC9 tumors show 
widespread cytoplasmic positive ERK1/2 staining and 
phospho-ERK1/2 nuclear positivity. BCLC9-miR122 
tumors show cytoplasmic positive ERK1/2 staining, 
but no phospho-ERK1/2 (Supplementary Figure S4B). 
Concerning p38 and phospho-p38 status, BCLC9 tumors 
have weak cytoplasmic positivity for p38 protein and no 
nuclear phospho-p38 staining. On the contrary, BCLC9-
miR122 tumors show widespread cytoplasmic positivity 
for p38 and phospho-p38 is clearly localized in the cell 
nuclei, indicating active p38 protein. Staining pattern in 
BCLC9-miR122 tumors is comparable to that of mouse 
healthy liver, used as a reference of quiescent liver. Thus, 
restoration of miR122 induces a dormant state that can be 
reverted by TGF-β-R1 pathway inhibition. Furthermore, 
we analyzed MYC expression during TGF-β-R1 inhibition 
and we found a significant increase in MYC protein load 
in BCLC9-miR122 cells (Figure 4D) and a significant 
decrease in p21 and p15 expression (Supplementary 
Figure S4C), confirming that TGF-β-R1 signalling 
pathways  exert a cytostatic role in BCLC9-miR122 cells. 
miR122 restores liver cell homeostasis in CSC
IPA results showed differential expression of several 
Forkhead box (FOX) transcription factors, FOXM1, 
FOXO1 and FOXO3A (Supplementary Figure S3C). 
FOXM1 down-regulation was confirmed in BCLC9-
miR122 compared to parental cells (Figure 5A). Since, 
FOXM1 has been associated to human epithelial 
progenitor cell expansion [19] and malignancy [20], 
the results support the activity of miR122 in CSC 
differentiation. FOXO3A functions downstream of 
several oncogenic pathways [21], including the ERK 
and PI3K-AKT signalling cascades [22] and it, also, 
decreases MYC expression [23]. We observed FOXO1 
and FOXO3A gene up-regulation in BCLC9-miR122 
cells in array platform and real-time PCR (Figure 5A). 
FOXO function is regulated through protein inactivation, 
consequently we investigated if protein increase is 
mirrored by active protein. We demonstrated that the 
percentage of phosphorylated FOXO3A (indicative of 
protein inactivation) was significantly lower in BCLC9-
miR122 cells compared to parental cells (30% vs 80%) 
(Figure 5B). BCLC9-miR122 tumors show higher amount 
of nuclear active FOXO3A staining and minor phospho-
FOXO3A staining, compared to BCLC9 tumors and 
comparable to mouse quiescent liver (Figure 5C).
FOXO transcription factors are inactivated thanks to 
AKT activity. Most cancers exhibit elevated AKT activity 
due to increased growth factor signaling or oncogenic 
mutations [24]. Human AKT isoforms (AKT1, AKT2, and 
AKT3) display non-redundant cellular signaling activities: 
AKT1 is associated to negative cell cycle progression 
and proliferation [25], AKT2 contributes to metabolic 
signaling in the liver [26] and AKT3 is related to brain 
development [27]. We found a significant down-regulation 
in all AKT gene expression and in AKT2 and AKT3 
protein load in miR122 transfected cells (Supplementary 
Figure S5). AKT3 protein is almost knocked-down in 
BCLC9-miR122 cells compared to the high amounts 
of this kinase in parental cells, this ratifies AKT3 as a 
miR122 target [28] (Figure 6A). IHC confirmed that AKT3 
is highly expressed in BCLC9 tumors, it is reduced in 
BCLC9-miR122 tumors and completely absent in mouse 
healthy liver (Figure 6B). 
Since TGF-β can also activate PI3K through 
phosphorylation of its effector AKT [29], we wanted 
to know if rescue in malignant behavior in BCLC9-
miR122 cells due to TGF-β-R1 inhibition, were supported 
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Figure 3: miR122 do not activate canonical TGFβ pathway. (A) SMAD2, SMAD3, and phospho-SMAD3 IB with (+) and 
without (-) TGF-β-R1 inhibitor treatment. β-Actin is used as control protein load. (B) IB quantification of SMAD2, SMAD3 and phospho-
SMAD3. Phosphorylated proteins are expressed as a percentage of their total forms. (C) Analysis of SMAD2/SMAD3 expression and 
phosphorylation in xenograft tumors. Scale bars, 50 µm. p-SMAD3 stainings show a magnification to see cell stroma positive signal. 
(D) TGF-β-R1 inhibitor effects at a concentration of 10 and 1 µM for 48 hours on cell growth kinetics. Treatment is compared to vehicle 
(DMSO) treated cells.
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Figure 4: TGF-β-R1 kinase inhibition in BCLC9-miR122. (A) IB analysis of total p38, phosphorylated-p38, total ERK1&2, 
phosphorylated-ERK1&2, with (+) and without (-) TGF-β-R1 inhibitor treatment. β-Actin as control protein load. (B) IB quantification of 
total p38, phosphorylated-p38, total ERK1&2, and phosphorylated-ERK1&2. Phosphorylated kinases are expressed as a percentage of the 
total protein.  (C) Ratio phospho-ERK1&2/phospho-p38 with and without TGF-β-R1 inhibitor treatment.  (D) IB analysis of MYC with (+) 
and without (–) treatment with TGF-β-R1 inhibitor (1 µM, 48 h). β-Actin as control protein load.
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Figure 5: miR122 modulates FOX gene family expression. (A) FOXM1, FOXO1, and FOXO3A gene expression by real-time PCR. 
Results are normalized against RPLP0 gene. (B) FOXO3A protein expression and phosphorylation were analyzed by IB. Phosphorylated 
kinases are expressed as a percentage of the total protein. (C) FOXO3A protein expression and phosphorylation analyzed in xenograft 
tumors by IHC staining. Mouse healthy liver was used as a control for quiescent normal liver. Scale bars, 50 µm.
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by AKT up-regulated expression and/or activation. 
TGF-β-R1 inhibition in BCLC9-miR122 cells induced 
the recovery of AKT2 to the levels observed in parental 
BCLC9 cells, but AKT3 levels remained nearly 
undetectable in BCLC9-miR122 (Figure 6C). Percentage 
of phosphorylated AKT2 over total AKT2 protein load, 
showed that BCLC9-miR122 cells, with or without 
TGF-β-R1 inhibitor treatment, do not phosphorylate 
AKT2, although this treatment induces an increase 
in AKT2 isoform (Figure 6D). We treated parental 
and miR122 transfected cells with IGF1, one of the 
main triggers of AKT activation. AKT2 isoform was 
phosphorylated after IGF1 treatment in parental BCLC9 
cells but not in BCLC9-miR122 cells. AKT1 shows a 
steady activation through all conditions tested (Figure 6E). 
To revise the responsiveness of BCLC9-miR122 to IGF1, 
we used insulin for AKT activation and we found a 
significant AKT2 phosphorylation in both BCLC9 and 
BCLC9-miR122 cells (Figure 6F). This result indirectly 
confirms IGF1R as a miR122 target gene [30].
AKT3 silencing partially reproduces miR122 
effects on CSC cells
We silenced AKT3 expression in BCLC9 cells to 
define AKT3 involvement in HCC. We achieved up to a 
76% of gene silencing, measured by IB, and confirmed 
by real-time PCR (Supplementary Figure S6A). AKT3 
knocked-down cells (BCLC9-AKT3 KD) show an 
adherent phenotype comparable to that of BCLC9-miR122 
cells (Supplementary Figure S6B) and a lower cell 
proliferation ratio in vitro (Figure 7A). This agrees with 
a decrease in expression of CCNA2, CCND1 and CCNE1 
in BCLC9-AKT3 KD cells compared to parental and 
BCLC9-miR122 cells. CCNG1 increased expression is 
justified by the fact that cyclin G1 is a miR122 target gene. 
On the contrary, p21 and p15 expression in BCLC9-AKT3 
KD cells is similar to that showed by parental BCLC9 cells 
(Figure 7B). AKT3 silenced cells showed significantly 
reduced MYC and KLF4 expression but, we only detected 
a moderate decrease in MYC protein load (Figure 7C). 
BCLC9-AKT3 KD cells upregulate FOXO3A gene 
expression similarly as BCLC9-miR122 cells, but FOXO1 
expression do not follow the same trend (Supplementary 
Figure S6C). AKT1, AKT2 and AKT3 expression are 
down-regulated in BCLC9-AKT3 KD cells as observed in 
BCLC9-miR122 cells (Supplementary Figure S6D). IGF1 
and insulin treatments, induced AKT2 phosphorylation in 
AKT3 silenced cells. Thus, our results demonstrate that 
miR122 is the unique responsible for rendering BCLC9-
miR122 insensitive to IGF1 (Figure 7D). 
We analyzed the potential induction of dormancy 
program in BCLC9-AKT3 KD cells. We observed 
that, differently from BCLC9-miR122 cells, phospho-
ERK1/2:phospho-p38 ratio in BCLC9-AKT3 KD cells 
was comparable to that in parental BCLC9, clearly 
favouring phospho-ERK1/2 over phospho-p38 (Figure 7E 
and Supplementary Figure S6E). 
To analyze AKT3-KD cells tumorigenic potential, 
we reproduced exactly the same protocol previously done 
in BCLC9-miR122 xenografts. BCLC9-AKT3 KD cells 
originated tumors which size is halfway between those 
obtained from parental BCLC9 and BCLC9-miR122 cells 
(Figure 7F). Although AKT3 absence partially reproduces 
the effects induced by miR122 expression in BCLC9 cells, 
it is not enough to fully reduce tumor size. However, they 
are smaller and hence, still less aggressive than those 
derived from parental BCLC9 cells.
DISCUSSION 
miR122 is one of the most abundant miRNAs in 
the adult healthy liver but absent in fetal liver and this is 
suggestive that miR122 is crucial in organ development. 
miR122 promotes hepatobiliary segregation and the 
acquisition and maintenance of a hepato-specific 
phenotype [8, 31]. Since miR122 is key in hepatocyte 
differentiation [9], the reported miR122 down-regulation 
in a high percentage of HCCs, is justified. The existence of 
liver CSCs is supported by multiple publications [32] and 
they determine  HCC poor prognosis and treatment failure. 
This backed up the rationale of evaluating the competence 
of miR122 to revert the cancer stem-like behavior and 
phenotype exhibited by BCLC9 cells. Multiple sets of cell 
markers are presumed to be associated to a pluripotent 
and/or progenitor cell profile [33] in the liver.  Available 
information on this subject, indicates that there is not 
a sole panel of liver CSC markers but a distinctive 
CSC behavior, being the main trait the ability in tumor 
induction [34]. 
BCLC9 is a human HCC cell line which displays 
a wide range of CSC markers and has high tumorigenic 
potential. miR122 transfection in BCLC9 cells is able to 
reduce significantly the expression of KLF4 and MYC 
genes, both associated to cell pluripotency. KLF4 is 
considered to be critical for the maintenance of breast 
cancer stem cells [35] and to induce cancer development 
[36].  MYC’s central role in cell reprogramming is, also, 
thoroughly documented [37, 38] as well as its contribution 
to neoplastic transformation [39, 40]. On the other hand, 
CD133 and EpCAM are significantly up-regulated in 
BCLC9-miR122 cells. CD133 has been considered for a 
long time a marker for CSCs but there is no consensus on 
the real contribution of CD133 in the potential of inducing 
new tumors [41]. On the contrary, EpCAM is a well-
established marker for TICs, cancer cells and stem cells 
[42]. EpCAM contribution to CSC behavior is associated 
to the induction of MYC, KLF4, SOX2, NANOG and 
OCT4 expression [43] provided that EpCAM molecule is 
processed [44]. Therefore, the mere presence of EpCAM 
does not necessarily imply the acquisition of CSC traits, 
since EpCAM’s activation is mandatory. 
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Figure 6: miR122 regulates AKT expression and activation. (A) IB detection and analysis of AKT1, AKT2, and AKT3 protein 
expression. β-Actin as control protein load. (B) AKT3 detection by IHC in tumors generated by parental and miR122 transfected cells. 
Mouse healthy liver was used as control of quiescent liver. Scale bars, 50 μm. (C) IB quantification of AKT1, AKT2, AKT3 and their 
phosphorylated forms in parental and miR122 transfected cells with (+) and without (-) TGF-β-R1 inhibitor (1 µM, 48 h). (D) Percentage 
of activated AKT1 and AKT2 isoforms against total load of AKT1 and AKT2 respectively. (E) IB detecting AKT1, AKT2, AKT3 and 
their phosphorylated forms in parental and miR122 transfected cells with (+) and without (-) IGF-1 treatment (10 ng/mL, 30 min.). (F) IB 
detecting AKT1, AKT2, AKT3 and their phosphorylated forms in parental and miR122 transfected cells with (+) and without (-) Insulin 
treatment (1 µM, 1 h.).
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Figure 7: Effects of AKT3 knock-down. (A) Cell growth kinetics of parental BCLC9, BCLC9-miR122 and AKT3 silenced BCLC9 
cells at different time points (t = 0, 24, 48, 96 and 144 hours). (B) CCNA2, CCND1, CCNE1 CCNG1, CDKN1A, CDKN2A, and CDKN2B 
gene expression determined by real-time PCR. Results are normalized against RPLP0 gene. (C) MYC and KLF4 gene expression determined 
by real-time PCR. Results are normalized against RPLP0 gene. MYC protein detection by IB and quantification. (D) Major tumor diameter 
(mm) obtained in BCLC9, BCLC9-miR122 and BCLC9-AKT3 KD tumors. (E) Ratios ERK1&2/p38 in BCLC9-AKT3 KD and parental 
cells. Ratios of phospho-ERK1&2/phospho-p38 are shown for both BCLC9-miR122 against parental cells and for BCLC9-AKT3 KD 
against parental cells. (F) IB showing the effects of IGF1 (10 ngr/mL, 30 min) and Insulin (1 µM, 1 h) treatments (+) on AKT2 expression 
and phosphorylation compared to untreated cells (–). Vertical lines are showing the boundaries in vertically sliced gels.
Oncotarget71324www.impactjournals.com/oncotarget
Studies performed by Wang and collaborators 
have shown a potential reciprocal regulation of MYC 
and miR122 in HCC [45]. In agreement with this, we 
demonstrated that BCLC9-miR122 cells show a lower 
cell proliferation rate both in vitro and in in vivo setting. 
Xenograft tumors derived from BCLC9-miR122 cells 
are significantly smaller than those generated by parental 
BCLC9 cells. BCLC9-miR122 reveal a significant 
decrease in cyclins A2, E1, and G1 and a higher expression 
of p21, p15 and p16. Not surprisingly, results of array 
analysis comparing BCLC9-miR122 and BCLC9 cells, 
revealed an increase in expression of genes involved in 
cell cycle arrest, and a decrease in DNA replication and 
cancer pathway-associated genes. 
The increase in p21, p15 and p16 expression 
is related to cell cycle arrest in both quiescence and 
senescence cell programs [46]. While in cell senescence 
cell growth-promoting pathways are still active [47, 48], 
in cell quiescence cell cycle arrest goes with a down-
regulation of growth-promoting gene expression [49, 50]. 
The increase in p21 and p15 gene expression [51] and 
MYC gene down-regulation [15] are gene responses 
associated to TGF-β  cytostatic activity. Here we 
demonstrate TGF-β cytostatic role in BCLC9-miR122 
cells by inhibiting TGF-β-R1 kinase activation. After 
treatment, miR122 transfected cells increased MYC 
protein load, down-regulated p21 and p15 expression and 
recovered cell proliferation rate. So, our results support 
the fact of BCLC9-miR122 cells being in a quiescent state 
because we are able to reverse this state by inhibiting 
TGF-β-R1 activation and we are able to demonstrate a 
down-regulation of IGF1R activity, one of the prevalent 
growth-promoting genes in malignant cells.
Cancer cell dormancy is defined by a low 
ERK1/2:p38 ratio [18]. BCLC9-miR122 cells show 
increased expression of p38 compared to parental cells and 
the same happens when we determine the ratio of activated 
forms, phosphoERK1/2:phospho-p38. So, miR122 
transfected BCLC9 cells enter in a dormant state and 
treatment with TGF-β-R1 kinase inhibitor reverts those 
ratios, thus confirming the exit of dormancy and resuming 
the high proliferative phenotype in BCLC9-miR122 cells.
IPA analysis unveiled the role of FOX family of 
transcriptional regulators in BCLC9 cell differentiation. 
FOXM1 overexpression has been confirmed in a wide 
range of human cancers and, also, associated to induction 
of human epithelial progenitor cell expansion [19]. FOXM1 
transcription factor coordinates a network of genes that 
function warranting correct cell cycle progression and exit 
[52]. We found a significant down-regulation of FOXM1 
gene expression in BCLC9-miR122 cells compared to 
parental BCLC9 cells, thus providing more evidences 
towards cell differentiation induced by miR122 expression.
FOXO transcription factors are negative regulators 
of cell proliferation and survival and consequently, they are 
regarded as tumor suppressors. Thus, loss or inactivation of 
FOXO proteins, and particularly FOXO3A, will increase 
resistance to apoptosis and induce cell-cycle progression 
[53]. This is especially true in tumors since FOXO 
proteins act downstream of several oncogenic pathways 
[21] such as ERK or PI3K/AKT [22]. As a matter of fact, 
both are pathways regulated by non-canonical TGF-β 
signaling pathway [29]. BCLC9-miR122 cells show a 
significant increase in FOXO3A expression confirmed 
by an increase in protein load compared to parental cells 
and a reduced percentage of inactivated FOXO3A. So, 
miR122 expression is rendering BCLC9 cells to a more 
“well-behaved” phenotype. Activated AKT stimulate cell 
growth and proliferation, similarly to the effects observed 
in response to enhanced expression of MYC [54]. While 
miR122 restoration induced AKT2 and AKT3 significant 
down-regulation in HCC cells, treatment with TGF-β-R1 
kinase inhibitor rescued only AKT2 expression. Since 
AKT3 is a miR122 target, its expression remained almost 
silenced in miR122 transfected cells whatever treatment 
we applied. Moreover, BCLC9-miR122 transfected cells 
only phosphorylate AKT2 kinase under insulin but not 
IGF1 treatment. This, indirectly confirms IGF1R as a gene 
target of miR122. Since miR122 down-regulation occurs 
frequently in HCC, upregulation of AKT3 kinase is almost 
an unavoidable event in this neoplasm. 
The role of AKT3 in HCC is not known, so silencing 
AKT3 isoform in BCLC9 cells determined the effects of 
miR122 due to AKT3 down-regulation. AKT3 silencing 
rendered cells more adherent to the culture plate and less 
proliferative than parental cells, probably due to down-
regulation in expression of several cyclins, but not in their 
corresponding cyclin kinase inhibitors. Since CDKNs 
are direct targets of TGF-β pathway, our results ratify 
its cytostatic role in BCLC9-miR122 but not in BCLC9-
AKT3 KD cells. Quiescence program was well-defined 
in BCLC9-miR122 cells, but BCLC9-AKT3 KD cells 
were not able to activate p38 MAPK in order to keep the 
low p-ERK1/2:p-p38 ratio that defines dormancy, thus 
BCLC9-AKT3 KD tumors were bigger than BCLC9-
miR122 tumors but smaller than those from BCLC9 cells. 
AKT3 silenced cells reproduce the expression of FOXM1 
and FOXO3A obtained in BCLC9-miR122 cells, but not 
for FOXO1 which expression was clearly down-regulated 
in BCLC9-AKT3 KD cells. In addition, BCLC9-AKT3 
KD cells are responsive to IGF1 and insulin treatment, 
since both induced AKT2 phosphorylation. 
Differences between the effects achieved by 
silencing AKT3 (in a setting of miR122 absence) and 
miR122 reestablishment, define the key facts in tumor 
cell dormancy: increase in functional p38 and cell cycle 
progression inhibitors p21 and p15, modulation of IGF1/
IGF1R signaling pathway which, in turn, regulates AKT2 
activation and subsequent FOXO activity. In BCLC9 cells, 
MYC is undoubtedly linked to all pathways regulated by 
miR122 and MYC expression recovery marks the shift in 
TGF-β activity, from tumor suppressor to oncogene. 
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Despite the major advances in HCC treatment 
options [55], therapeutic efficacy is still conditional to 
underlying liver disease and tumor recurrence. So, it should 
be key to have a therapy that could work at several fronts. 
We reestablished miR122 expression in a distinctive 
human HCC cell line - the BCLC9 cell line. Its uniqueness 
relies on the fact that these cells show a complete set of 
stem/pluripotency stem cell markers, they usually grow 
forming spheroid structures and they show high efficiency 
as tumor initiating cells.  Moreover, no other cell line 
displays such stem cell profile. 
Our study demonstrates that restitution of miR122 
expression, in addition of functioning in stem/progenitor 
liver cells on a normal basis, is able to reduce tumor growth 
by inducing tumor cell dormancy in a human HCC cell line 
with a consistent stem-like profile. Reestablishing miR122 
expression should be considered as a potential therapeutic 
strategy since it would work concurrently reducing 
tumor aggressiveness and decreasing HCC recurrence by 
favouring stem-like tumor cell differentiation. 
MATERIALS AND METHODS
Cell lines 
BCLC9 cells were generated as previously 
described12. Standard culture medium for BCLC9 cell 
lines is Dulbecco’s Modified Eagle Medium (DMEM) 
high glucose (Sigma-Aldrich, St Louis, MO) and HAM 
F12 (Sigma-Aldrich, St Louis, MO) (1:1). Medium is 
supplemented with: 1% Na Pyruvate 100 mM (Sigma-
Aldrich, St Louis, MO), 1% Pen/Strep 10000 U/mL (Lonza 
Group Ltd, Switzerland), 1% L-Gln 200 mM (Sigma-
Aldrich, St Louis, MO), 1% Non-Essential Aminoacids 
(NEAA) (Lonza Group Ltd, Switzerland), 10% FBS 
(Life Technologies). BCLC9-miR122 and BCLC9-AKT3 
KD culture medium is supplemented with neomycin 
(G418 disodium salt, Sigma-Aldrich, Germany; at a final 
concentration of 500 μgr/mL) and puromycin (Sigma-
Aldrich, Germany; at a final concentration of 10 μgr/mL) 
respectively, once a week to keep selective pressure. 
Cell treatments
1 µM of TGFBR1 inhibitor (Merck #616452) in 1% 
DMSO for 48 h. 
10 ngr/mL IGF-1 (Sigma-Aldrich, St Louis, MO) in 
10 nM HCl as vehicle, for 30 minutes. 
Human insulin (Sigma-Aldrich, St Louis, MO) 1 µM 
for 1 h. Lyophilized insulin is resuspended in HEPES buffer 
and it is diluted in culture medium so control cells were 
treated with a final concentration of HEPES at 14.5 µM. 
Control untreated cells were cultured for the same 
time period with the corresponding vehicles: 1% DMSO; 
10 nM HCl or 14.5 µM HEPES in cell culture medium 
without FBS.
Generation of overexpression and knocked-down 
cells
BCLC9-miR122 cells were obtained by 
electroporation of pCMV6-GFP-MIR122 plasmid 
(MI0000442, OriGene Technologies. Rockville, MD). 
BCLC9-AKT3 KD stable cell line was obtained by 
lentiviral infection of pGFP-C-shAKT3 (TL320629, 
OriGene Technologies. Rockville, MD). To obtain 
stable cell lines, cells were sorted twice by FACS. 
miR122 and AKT3 expression was checked by means 
of real-time PCR using specificTaqMan expression 
assays (Applied Biosystems, Life Technologies) to 
detect mature miR122 and AKT3 expression. Treatment 
with neomycin once a week keeps selective pressure 
on miR122-positive cells and puromycin treatment on 
AKT3 silenced cells. 
Cell proliferation assay (MTT)
Cell viability and proliferation is determined by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay (Sigma-Aldrich, St Louis, MO) 
following manufacturer’s instructions. Cells are seeded in 
96 well plates and their viability is determined at 0, 24, 
48, 72 and 96 hours of cell culture, each time point in 
triplicates. A byproduct of cell metabolism is measured at 
570 nm in a microplate reader (FLUOstar Optima, BMG 
Labtechnologies Ltd., UK). 
Cell cycle analysis by flow cytometry
Parental BCLC9 and BCLC9-miR122 subconfluent 
cell cultures are analyzed using Hoechst 33342 
(Molecular Probes, Invitrogen)  in unfixed cells. Fixation 
and permeabilization is not needed for labelling cells 
but physiologic conditions are required because dye 
internalization is done by the ATP-binding cassette 
(ABC) transporter activity. Simultaneously, we used 
Propidium Iodide (PI) (Molecular Probes, Invitrogen)  as 
non-vital DNA dye to discriminate dead cells [56, 57]. 
Data on DNA content is acquired in a flow cytometer 
(BD LSRFORTESSATM X-20) and data is analyzed in 
FACSDivaTM Software Version 6.1.3.
Nucleic acid extraction
MirVanaTM miRNA isolation Kit (Ambion, Life 
Technologies) was used to isolate total RNA (including 
miRNAs) according to manufacturer’s protocol. Genomic 
DNA (gDNA) was purified from cell cultures by means 
of phenol:chloroform method, following the protocol 
of Sambrook and Russell [58]. Total gDNA and RNA 
concentration and purity was measured in a NanoDrop 
ND-1000 Spectrophotometer (Thermo Scientific, 
Wilmington DE).
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cDNA microarray analysis
Total RNA was extracted from three independent 
BCLC9 and BCLC9-miR122 cell batches. RNA samples 
were further analyzed for its concentration and quality and 
were hybridized to Human Genome U219 GeneChip from 
Affymetrix (Affymetrix, Santa Clara, CA) and labeled. 
The labelled arrays were scanned with a GeneChip scanner 
3000 (Affymetrix, Santa Clara, CA). Microarray data were 
normalized using the guanidine-cytosine content-adjusted 
robust multiarray algorithm, which computes expression 
values from probe-intensity values incorporating probe-
sequence information.
Reverse transcription and real-time PCR
Two μgr of total RNA were used for reverse 
transcription using a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Life Technologies) 
following the manufacturer’s instructions. For multiplexed 
quantitative real-time PCR, 20 ngr of cDNA template were 
amplified by means of TaqMan Gene Expression Assay 
technology (Applied Biosystems, Life Technologies) 
in an ABI 7500 PCR system. Each target gene analyzed 
and huRPLP0 (housekeeping gene) were amplified 
simultaneously in each well to guarantee the homogeneity 
in technical replicates. In case of miR amplification, 
reverse transcription is performed using specific primers 
followed by monoplexed real-time PCR for target miR 
and RNU6B (housekeeping gene) genes. A complete list 
of TaqMan gene expression assays used can be found in 
Supplementary Table S1A.
Immunoblotting (IB)
For IB analyses, total protein and nuclear extracts 
were prepared as described previously [59, 60]. Total 
protein concentration was determined by BCA system 
(Pierce; Thermo Scientific, Wilmington, DE). 
Total protein (50 μgr/lane) or nuclear protein 
extracts (30 μgr/lane) were separated on SDS-PAGE 
reducing gels (BioRad, CA). Blots were hybridized with 
primary antibodies and positive bands were detected by 
RapidStep enhanced chemiluminescence (ECL) Reagent 
(Calbiochem, Merck, Germany). IB were quantified using 
ImageJ 1.46r software (National Institute of Health, USA).
Primary and secondary antibodies used are listed in 
Supplementary Table S1B. 
Animal experiments
Severe Combined Immuno Deficiency (SCID) mice 
(CB17/lcr-Prkdcscid/lcrlcoCrl mouse, were purchased 
from Charles River (Charles River Lab International Inc. 
Wilmington, MA) and maintained under pathogen-free 
conditions in University of Barcelona animal facilities. 
Procedures involving animals and their care followed 
institutional guidelines. Four groups of 6–8 week-old 
SCID mice (n = 5/group) were used. Mice were injected 
subcutaneously (s.c.) in the right flank with 1·106 cells in 
Phosphate Buffered Saline (PBS). First group mice were 
injected with 1·106 parental BCLC9 cells, the second 
group with 1·106 BCLC9-miR122 cells and the third group 
of mice with 1·106 BCLC9-AKT3 KD cells. The fourth 
group received vehicle (PBS). Animals were examined 
three times per week, after 30 days all mice were 
euthanized by cervical dislocation. Tumors were excised 
and their maximum and minimum diameters measured. 
Tumors were divided in two parts, one was snap-frozen for 
RNA purification and the other half was fixed in formalin 
and embedded in paraffin for IHC studies.
Immunocytochemistry (ICC), 
Immunohistochemistry (IHC) and 
Immunofluorescence (IF)
IF was performed on cultured cells previously 
seeded onto poly-lysine treated cover glasses and fixed 
with cold Methanol:Acetone (1:1). No antigen retrieval 
was necessary in these samples. IHC was performed 
on serial 4 μm sections of HCC xenograft samples, 
previously formalin fixed and paraffin embedded. Antigen 
retrieval was performed using PT-Link technology 
(Dako, Denmark). Diamino benzindine (DAB) detection 
system (EnVision+ System-HRP (DAB), Dako Denmark) 
was used to detect positive staining for specific primary 
antibodies. In case of immunofluorescence staining, 
secondary antibodies conjugated with Alexa-Fluor488 
or Alexa-Fluor568 were used (Molecular Probes. 
Invitrogen) and Hoechst 33342 (Molecular Probes. 
Invitrogen) for nuclei counterstain. Stainings were 
analyzed using an Olympus BX51 microscope equipped 
with DP71 camera (Olympus Europa SE & CO.KG. 
Germany).
Primary and secondary antibodies used are listed in 
Supplementary Table S1B. 
Statistical analysis
Data were analyzed using two-tailed Student’s t test 
to compare two groups using GaphPad Software Inc, 
5.0 (La Jolla, CA, USA). P values to assess statistical 
significance are as follows: *P < 0.05; **P < 0.01; 
***P < 0.001. Data for all figures are expressed as the 
means + SD of, at least, 3 independent experiments. 
Statistics for microarray analysis is detailed in 
Supplementary Materials and Methods.
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